Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Total 13F shares
-
1,892,924
-
Share change
-
+645,564
-
Total reported value
-
$5,108,432
-
Put/Call ratio
-
1095%
-
Price per share
-
$2.70
-
Number of holders
-
28
-
Value change
-
+$1,699,282
-
Number of buys
-
16
-
Number of sells
-
8
Institutional Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q1 2021
As of 31 Mar 2021,
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,892,924 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, COMMONWEALTH EQUITY SERVICES, LLC, PRICE T ROWE ASSOCIATES INC /MD/, QS Investors, LLC, HighMark Wealth Management LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and HATTON CONSULTING, INC..
This page lists
28
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.